The MammaPrint test, which predicts the likelihood of breast cancer metastasis with exceptional accuracy, is now accessible to the general public.
Previously available only in research settings, MammaPrint is now reimbursed by leading health insurer Achmea Zilveren Kruis starting in 2020—a major advancement endorsed by the Netherlands Cancer Institute (NKI-AVL).
MammaPrint
Developed using pioneering DNA microarray technology—first applied in the Netherlands by NKI-AVL researchers at Antoni van Leeuwenhoek Hospital in Amsterdam—this test identifies metastasis risk at an early stage.
MammaPrint offers far greater precision than traditional methods. For low-risk patients, it can spare them the often grueling chemotherapy regimen.
Cost SavingsEach year, around 13,000 women in the Netherlands are diagnosed with breast cancer, the nation's most common cancer in women.
With wider access to MammaPrint, many patients enjoy improved quality of life while achieving substantial healthcare cost savings by avoiding intensive, expensive treatments.
